{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T12:52:14Z","timestamp":1791377534603,"version":"4.3.2"},"reference-count":106,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,24]],"date-time":"2025-07-24T00:00:00Z","timestamp":1753315200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,7,24]],"date-time":"2025-07-24T00:00:00Z","timestamp":1753315200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Lambert Initiative for Cannabinoid Therapeutics"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Eat Disord"],"DOI":"10.1186\/s40337-025-01328-5","type":"journal-article","created":{"date-parts":[[2025,7,24]],"date-time":"2025-07-24T08:13:16Z","timestamp":1753344796000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Psychedelic use in individuals living with eating disorders or disordered eating: findings from the international MED\u2013FED survey"],"prefix":"10.1186","volume":"13","author":[{"given":"Sarah-Catherine","family":"Rodan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noah","family":"Meez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Lloyd-Hurwitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel A.","family":"Bedoya-P\u00e9rez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anastasia","family":"Suraev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natasha","family":"Sommer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kayla","family":"Greenstien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Maguire","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iain S.","family":"McGregor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,24]]},"reference":[{"key":"1328_CR1","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.pharmthera.2018.11.010","volume":"197","author":"MW Johnson","year":"2019","unstructured":"Johnson MW, Hendricks PS, Barrett FS, Griffiths RR. Classic psychedelics: An integrative review of epidemiology, therapeutics, mystical experience, and brain network function. Pharmacol Ther. 2019;197:83\u2013102.","journal-title":"Pharmacol Ther"},{"issue":"2","key":"1328_CR2","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1556\/2054.2019.008","volume":"3","author":"G Samorini","year":"2019","unstructured":"Samorini G. The oldest archeological data evidencing the relationship of Homo sapiens with psychoactive plants: a worldwide overview. J Psychedelic Stud. 2019;3(2):63\u201380.","journal-title":"J Psychedelic Stud"},{"key":"1328_CR3","doi-asserted-by":"crossref","unstructured":"McKenna D, Riba J. New world tryptamine hallucinogens and the neuroscience of ayahuasca. Curr Top Behav Neurosci. 2016:283\u2013311.","DOI":"10.1007\/7854_2016_472"},{"issue":"3","key":"1328_CR4","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1007\/s12231-008-9033-8","volume":"62","author":"G Guzm\u00e1n","year":"2008","unstructured":"Guzm\u00e1n G. Hallucinogenic mushrooms in Mexico: an overview. Econ Bot. 2008;62(3):404\u201312.","journal-title":"Econ Bot"},{"issue":"2","key":"1328_CR5","doi-asserted-by":"publisher","first-page":"R63","DOI":"10.1016\/j.cub.2021.12.009","volume":"32","author":"B Kelmendi","year":"2022","unstructured":"Kelmendi B, Kaye AP, Pittenger C, Kwan AC. Psychedelics. Curr Biol. 2022;32(2):R63\u20137.","journal-title":"Curr Biol"},{"issue":"15","key":"1328_CR6","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1056\/NEJMoa2032994","volume":"384","author":"R Carhart-Harris","year":"2021","unstructured":"Carhart-Harris R, Giribaldi B, Watts R, Baker-Jones M, Murphy-Beiner A, Murphy R, et al. Trial of psilocybin versus escitalopram for depression. NEJM. 2021;384(15):1402\u201311.","journal-title":"NEJM"},{"issue":"2","key":"1328_CR7","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1007\/s00213-017-4771-x","volume":"235","author":"RL Carhart-Harris","year":"2018","unstructured":"Carhart-Harris RL, Bolstridge M, Day C, Rucker J, Watts R, Erritzoe D, et al. Psilocybin with psychological support for treatment-resistant depression: Six-month follow-up. Psychopharmacology. 2018;235(2):399\u2013408.","journal-title":"Psychopharmacology"},{"issue":"7","key":"1328_CR8","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1016\/S2215-0366(16)30065-7","volume":"3","author":"RL Carhart-Harris","year":"2016","unstructured":"Carhart-Harris RL, Bolstridge M, Rucker J, Day CM, Erritzoe D, Kaelen M, et al. Psilocybin with psychological support for treatment-resistant depression: An open-label feasibility study. Lancet Psychiatry. 2016;3(7):619\u201327.","journal-title":"Lancet Psychiatry"},{"key":"1328_CR9","doi-asserted-by":"publisher","first-page":"974","DOI":"10.3389\/fphar.2017.00974","volume":"8","author":"L Roseman","year":"2018","unstructured":"Roseman L, Nutt DJ, Carhart-Harris RL. Quality of acute psychedelic experience predicts therapeutic efficacy of psilocybin for treatment-resistant depression. Front Parmacol. 2018;8:974.","journal-title":"Front Parmacol"},{"issue":"5","key":"1328_CR10","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1177\/0022167817709585","volume":"57","author":"R Watts","year":"2017","unstructured":"Watts R, Day C, Krzanowski J, Nutt D, Carhart-Harris R. Patients\u2019 accounts of increased \u201cconnectedness\u201d and \u201cacceptance\u201d after psilocybin for treatment-resistant depression. J Humanist Psychol. 2017;57(5):520\u201364.","journal-title":"J Humanist Psychol"},{"issue":"12","key":"1328_CR11","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1177\/0269881116675513","volume":"30","author":"RR Griffiths","year":"2016","unstructured":"Griffiths RR, Johnson MW, Carducci MA, Umbricht A, Richards WA, Richards BD, et al. Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: a randomized double-blind trial. J Psychopharmacol. 2016;30(12):1181\u201397.","journal-title":"J Psychopharmacol"},{"issue":"1","key":"1328_CR12","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1001\/archgenpsychiatry.2010.116","volume":"68","author":"CS Grob","year":"2011","unstructured":"Grob CS, Danforth AL, Chopra GS, Hagerty M, McKay CR, Halberstadt AL, et al. Pilot study of psilocybin treatment for anxiety in patients with advanced-stage cancer. Arch Gen Psychiatry. 2011;68(1):71\u20138.","journal-title":"Arch Gen Psychiatry"},{"issue":"12","key":"1328_CR13","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1177\/0269881116675512","volume":"30","author":"S Ross","year":"2016","unstructured":"Ross S, Bossis A, Guss J, Agin-Liebes G, Malone T, Cohen B, et al. Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial. J Psychopharmacol. 2016;30(12):1165\u201380.","journal-title":"J Psychopharmacol"},{"issue":"11","key":"1328_CR14","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1177\/0269881114548296","volume":"28","author":"MW Johnson","year":"2014","unstructured":"Johnson MW, Garcia-Romeu A, Cosimano MP, Griffiths RR. Pilot study of the 5-HT2AR agonist psilocybin in the treatment of tobacco addiction. J Psychopharmacol. 2014;28(11):983\u201392.","journal-title":"J Psychopharmacol"},{"issue":"3","key":"1328_CR15","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1177\/0269881114565144","volume":"29","author":"MP Bogenschutz","year":"2015","unstructured":"Bogenschutz MP, Forcehimes AA, Pommy JA, Wilcox CE, Barbosa PCR, Strassman RJ. Psilocybin-assisted treatment for alcohol dependence: a proof-of-concept study. J Psychopharmacol. 2015;29(3):289\u201399.","journal-title":"J Psychopharmacol"},{"key":"1328_CR16","doi-asserted-by":"crossref","unstructured":"Peck SK, Shao S, Gruen T, Yang K, Babakanian A, Trim J, et al. Psilocybin therapy for females with anorexia nervosa: a phase 1, open-label feasibility study. Nat Med. 2023.","DOI":"10.1038\/s41591-023-02455-9"},{"issue":"4","key":"1328_CR17","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1007\/s40519-020-01000-8","volume":"26","author":"MJ Spriggs","year":"2021","unstructured":"Spriggs MJ, Kettner H, Carhart-Harris RL. Positive effects of psychedelics on depression and wellbeing scores in individuals reporting an eating disorder. Eat Weight Disord. 2021;26(4):1265\u201370.","journal-title":"Eat Weight Disord"},{"issue":"2","key":"1328_CR18","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1007\/s40519-018-0619-6","volume":"25","author":"M Renelli","year":"2020","unstructured":"Renelli M, Fletcher J, Tupper KW, Files N, Loizaga-Velder A, Lafrance A. An exploratory study of experiences with conventional eating disorder treatment and ceremonial ayahuasca for the healing of eating disorders. Eat Weight Disord. 2020;25(2):437\u201344.","journal-title":"Eat Weight Disord"},{"issue":"1","key":"1328_CR19","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1186\/s40337-024-01125-6","volume":"12","author":"E Lacroix","year":"2024","unstructured":"Lacroix E, Fatur K, Hay P, Touyz S, Keshen A. Psychedelics and the treatment of eating disorders: Considerations for future research and practice. J Eat Disord. 2024;12(1):165.","journal-title":"J Eat Disord"},{"issue":"12","key":"1328_CR20","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1007\/s11920-022-01394-5","volume":"24","author":"N Gukasyan","year":"2022","unstructured":"Gukasyan N, Schreyer CC, Griffiths RR, Guarda AS. Psychedelic-assisted therapy for people with eating disorders. Curr Psychiatry Rep. 2022;24(12):767\u201375.","journal-title":"Curr Psychiatry Rep"},{"key":"1328_CR21","unstructured":"Rodan S-C, Aouad P, Maguire S, McGregor IS. Psilocybin as a novel pharmacotherapy for treatment-refractory anorexia nervosa. OBM Neurobiol. 2021;5(2)."},{"key":"1328_CR22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.euroneuro.2023.05.008","volume":"75","author":"A Calder","year":"2023","unstructured":"Calder A, Mock S, Friedli N, Pasi P, Hasler G. Psychedelics in the treatment of eating disorders: rationale and potential mechanisms. Eur Neuropsychopharmacol. 2023;75:1\u201314.","journal-title":"Eur Neuropsychopharmacol"},{"key":"1328_CR23","first-page":"e20220597","volume":"46","author":"E Koning","year":"2024","unstructured":"Koning E, Brietzke E. Psilocybin-assisted psychotherapy as a potential treatment for eating disorders: a narrative review of preliminary evidence. Trends Psychiatr Psychother. 2024;46:e20220597.","journal-title":"Trends Psychiatr Psychother"},{"key":"1328_CR24","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1016\/j.physbeh.2015.06.007","volume":"152","author":"J Treasure","year":"2015","unstructured":"Treasure J, Cardi V, Leppanen J, Turton R. New treatment approaches for severe and enduring eating disorders. Physiol Behav. 2015;152:456\u201365.","journal-title":"Physiol Behav"},{"key":"1328_CR25","doi-asserted-by":"crossref","unstructured":"American Psychiatric Association A. Diagnostic and statistical manual of mental disorders: DSM-5. 5th ed. Washington, DC: Am Psychiatr Publ; 2013.","DOI":"10.1176\/appi.books.9780890425596"},{"issue":"1","key":"1328_CR26","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1186\/s40337-023-00833-9","volume":"11","author":"S-C Rodan","year":"2023","unstructured":"Rodan S-C, Bryant E, Le A, Maloney D, Touyz S, McGregor IS, et al. Pharmacotherapy, alternative and adjunctive therapies for eating disorders: findings from a rapid review. J Eat Disord. 2023;11(1):112.","journal-title":"J Eat Disord"},{"issue":"14","key":"1328_CR27","doi-asserted-by":"publisher","first-page":"1242","DOI":"10.1001\/jama.2025.0132","volume":"333","author":"E Attia","year":"2025","unstructured":"Attia E, Walsh BT. Eating disorders: a review. JAMA. 2025;333(14):1242\u201352.","journal-title":"JAMA"},{"key":"1328_CR28","doi-asserted-by":"crossref","unstructured":"Rodan S-C, Maguire S, Meez N, Greenstein K, Zartarian G, Mills KL, et al. Prescription and non-prescription drug use among people with eating disorders. JAMA Netw Open. 2025;8(7).","DOI":"10.1001\/jamanetworkopen.2025.22406"},{"issue":"2","key":"1328_CR29","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.jbi.2008.08.010","volume":"42","author":"PA Harris","year":"2009","unstructured":"Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap)\u2013a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform. 2009;42(2):377\u201381.","journal-title":"J Biomed Inform"},{"key":"1328_CR30","unstructured":"RCoreTeam. R: A language and environment for statistical computing (Version 4.3.2) [Computer software] 2023 [Available from: https:\/\/www.R-project.org\/."},{"key":"1328_CR31","unstructured":"Christensen R. ordinal\u2014Regression Models for Ordinal Data (Version 2023.12-4.1) [R package] 2023 [Available from: https:\/\/CRAN.R-project.org\/package=ordinal."},{"issue":"1","key":"1328_CR32","doi-asserted-by":"publisher","first-page":"2929","DOI":"10.1038\/s41598-024-53188-9","volume":"14","author":"JJ Breeksema","year":"2024","unstructured":"Breeksema JJ, Niemeijer A, Krediet E, Karsten T, Kamphuis J, Vermetten E, et al. Patient perspectives and experiences with psilocybin treatment for treatment-resistant depression: a qualitative study. Sci Rep. 2024;14(1):2929.","journal-title":"Sci Rep"},{"issue":"9","key":"1328_CR33","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1007\/s40263-020-00748-y","volume":"34","author":"JJ Breeksema","year":"2020","unstructured":"Breeksema JJ, Niemeijer AR, Krediet E, Vermetten E, Schoevers RA. Psychedelic treatments for psychiatric disorders: a systematic review and thematic synthesis of patient experiences in qualitative studies. CNS Drugs. 2020;34(9):925\u201346.","journal-title":"CNS Drugs"},{"issue":"2","key":"1328_CR34","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1191\/1478088706qp063oa","volume":"3","author":"V Braun","year":"2006","unstructured":"Braun V, Clarke V. Using thematic analysis in psychology. Qual Res Psychol. 2006;3(2):77\u2013101.","journal-title":"Qual Res Psychol"},{"issue":"4","key":"1328_CR35","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1080\/16066350500102237","volume":"13","author":"L Berends","year":"2005","unstructured":"Berends L, Johnston J. Using multiple coders to enhance qualitative analysis: The case of interviews with consumers of drug treatment. Addict Res Theory. 2005;13(4):373\u201381.","journal-title":"Addict Res Theory"},{"key":"1328_CR36","doi-asserted-by":"publisher","DOI":"10.1016\/0147-1767(85)90062-8","volume-title":"Naturalistic inquiry","author":"YS Lincoln","year":"1985","unstructured":"Lincoln YS, Guba EG. Naturalistic inquiry. Los Angeles: Sage Publications; 1985."},{"issue":"1","key":"1328_CR37","doi-asserted-by":"publisher","first-page":"160940691773384","DOI":"10.1177\/1609406917733847","volume":"16","author":"LS Nowell","year":"2017","unstructured":"Nowell LS, Norris JM, White DE, Moules NJ. Thematic analysis:striving to meet the trustworthiness criteria. Int J Qual Methods. 2017;16(1):1609406917733847.","journal-title":"Int J Qual Methods"},{"issue":"7","key":"1328_CR38","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1177\/02698811231158245","volume":"37","author":"EI Kopra","year":"2023","unstructured":"Kopra EI, Ferris JA, Winstock AR, Kuypers KP, Young AH, Rucker JJ. Investigation of self-treatment with lysergic acid diethylamide and psilocybin mushrooms: findings from the global drug survey 2020. J Psychopharmacol. 2023;37(7):733\u201348.","journal-title":"J Psychopharmacol"},{"key":"1328_CR39","doi-asserted-by":"publisher","first-page":"104507","DOI":"10.1016\/j.drugpo.2024.104507","volume":"130","author":"S Lake","year":"2024","unstructured":"Lake S, Lucas P. The global psychedelic survey: consumer characteristics, patterns of use, and access in primarily anglophone regions around the world. Int J Drug Policy. 2024;130:104507.","journal-title":"Int J Drug Policy"},{"key":"1328_CR40","doi-asserted-by":"crossref","unstructured":"Cuttler C, Stueber A, Simone J, Mayo LM. Down the rabbit hole: a large-scale survey of psychedelic users\u2019 patterns of use and perceived effects. J Psychoact Drugs.1\u201313.","DOI":"10.1080\/02791072.2025.2452226"},{"issue":"2","key":"1328_CR41","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1089\/psymed.2023.0002","volume":"1","author":"S Lake","year":"2023","unstructured":"Lake S, Lucas P. The Canadian psychedelic survey: characteristics, patterns of use, and access in a large sample of people who use psychedelic drugs. Psychedelic Med. 2023;1(2):98\u2013110.","journal-title":"Psychedelic Med"},{"key":"1328_CR42","unstructured":"Health AIo, Welfare. Hallucinogens in the NDSHS. Canberra: AIHW; 2024."},{"key":"1328_CR43","unstructured":"ONS. Drug misuse in England and Wales: Appendix tables, year ending march 2023. 2024 [Available from: https:\/\/www.ons.gov.uk\/peoplepopulationandcommunity\/crimeandjustice\/datasets\/drugmisuseinenglandandwalesappendixtable."},{"key":"1328_CR44","unstructured":"Canada H. Canadian alcohol and drugs survey (CADS): summary of results for 2023. government of Canada. 2024."},{"key":"1328_CR45","unstructured":"SAMHSA. Key substance use and mental health indicators in the United States. 2024."},{"issue":"1","key":"1328_CR46","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/s40337-023-00745-8","volume":"11","author":"H Melles","year":"2023","unstructured":"Melles H, Jansen A. Transdiagnostic fears and avoidance behaviors in self-reported eating disorders. J Eat Disord. 2023;11(1):19.","journal-title":"J Eat Disord"},{"issue":"4","key":"1328_CR47","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1111\/dar.12158","volume":"34","author":"J Kelly","year":"2015","unstructured":"Kelly J, Davis C, Schlesinger C. Substance use by same sex attracted young people: prevalence, perceptions and homophobia. Drug Alcohol Rev. 2015;34(4):358\u201365.","journal-title":"Drug Alcohol Rev"},{"issue":"6","key":"1328_CR48","doi-asserted-by":"publisher","first-page":"e2419137","DOI":"10.1001\/jamanetworkopen.2024.19137","volume":"7","author":"K Closson","year":"2024","unstructured":"Closson K, Boyce SC, Johns N, Inwards-Breland DJ, Thomas EE, Raj A. Physical, sexual, and intimate partner violence among transgender and gender-diverse individuals. JAMA Netw Open. 2024;7(6):e2419137.","journal-title":"JAMA Netw Open"},{"issue":"1","key":"1328_CR49","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1177\/10775595231226331","volume":"30","author":"DJ Higgins","year":"2024","unstructured":"Higgins DJ, Lawrence D, Haslam DM, Mathews B, Malacova E, Erskine HE, et al. Prevalence of diverse genders and sexualities in Australia and associations with five forms of child maltreatment and multi-type maltreatment. Child Maltreat. 2024;30(1):21\u201341.","journal-title":"Child Maltreat"},{"issue":"8","key":"1328_CR50","doi-asserted-by":"publisher","first-page":"1531","DOI":"10.1007\/s10964-023-01786-7","volume":"52","author":"L Sares-J\u00e4ske","year":"2023","unstructured":"Sares-J\u00e4ske L, Czimbalmos M, Majlander S, Siukola R, Klemetti R, Luopa P, et al. Gendered differences in experiences of bullying and mental health among transgender and cisgender youth. J Youth Adolesc. 2023;52(8):1531\u201348.","journal-title":"J Youth Adolesc"},{"issue":"11","key":"1328_CR51","doi-asserted-by":"publisher","first-page":"2199","DOI":"10.2105\/AJPH.2014.302106","volume":"104","author":"L Nuttbrock","year":"2014","unstructured":"Nuttbrock L, Bockting W, Rosenblum A, Hwahng S, Mason M, Macri M, et al. Gender abuse, depressive symptoms, and substance use among transgender women: a 3-year prospective study. Am J Publ Health. 2014;104(11):2199\u2013206.","journal-title":"Am J Publ Health"},{"key":"1328_CR52","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.drugalcdep.2015.04.008","volume":"152","author":"AS Keuroghlian","year":"2015","unstructured":"Keuroghlian AS, Reisner SL, White JM, Weiss RD. Substance use and treatment of substance use disorders in a community sample of transgender adults. Drug Alcohol Depend. 2015;152:139\u201346.","journal-title":"Drug Alcohol Depend"},{"key":"1328_CR53","doi-asserted-by":"publisher","first-page":"107397","DOI":"10.1016\/j.addbeh.2022.107397","volume":"134","author":"C Dyar","year":"2022","unstructured":"Dyar C, Kaysen D, Newcomb ME, Mustanski B. Event-level associations among minority stress, coping motives, and substance use among sexual minority women and gender diverse individuals. Addict Behav. 2022;134:107397.","journal-title":"Addict Behav"},{"key":"1328_CR54","doi-asserted-by":"publisher","first-page":"103747","DOI":"10.1016\/j.drugpo.2022.103747","volume":"105","author":"J Freestone","year":"2022","unstructured":"Freestone J, Prestage G, Bourne A, Ezard N, Race K, Nedanoski A, et al. Controlling for pleasure and risk: the experiences of sexuality and gender diverse people who use GHB. Int J Drug Policy. 2022;105:103747.","journal-title":"Int J Drug Policy"},{"issue":"7","key":"1328_CR55","doi-asserted-by":"publisher","first-page":"1940","DOI":"10.1111\/dar.13915","volume":"43","author":"S Bailey","year":"2024","unstructured":"Bailey S, Lin A, Cook A, Winter S, Watson V, Wright-Toussaint D, et al. Substance use among trans and gender diverse young people in Australia: patterns, correlates and motivations. Drug Alcohol Rev. 2024;43(7):1940\u201353.","journal-title":"Drug Alcohol Rev"},{"issue":"1","key":"1328_CR56","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1186\/s40337-022-00597-8","volume":"10","author":"E Bryant","year":"2022","unstructured":"Bryant E, Spielman K, Le A, Marks P, Touyz S, Maguire S. Screening, assessment and diagnosis in the eating disorders: findings from a rapid review. J Eat Disord. 2022;10(1):78.","journal-title":"J Eat Disord"},{"key":"1328_CR57","doi-asserted-by":"publisher","first-page":"101012","DOI":"10.1016\/j.nsa.2022.101012","volume":"1","author":"ECHM Haijen","year":"2022","unstructured":"Haijen ECHM, Hurks PPM, Kuypers KPC. Microdosing with psychedelics to self-medicate for ADHD symptoms in adults: a prospective naturalistic study. Neurosci Appl. 2022;1:101012.","journal-title":"Neurosci Appl"},{"issue":"2","key":"1328_CR58","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1007\/s00213-024-06685-8","volume":"242","author":"J Stroud","year":"2025","unstructured":"Stroud J, Rice C, Orsini A, Schlosser M, Lee J, Mandy W, et al. Perceived changes in mental health and social engagement attributed to a single psychedelic experience in autistic adults: results from an online survey. Psychopharmacology. 2025;242(2):373\u201387.","journal-title":"Psychopharmacology"},{"key":"1328_CR59","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.neuropharm.2018.01.049","volume":"142","author":"DJ Heal","year":"2018","unstructured":"Heal DJ, Gosden J, Smith SL. Evaluating the abuse potential of psychedelic drugs as part of the safety pharmacology assessment for medical use in humans. Neuropharmacology. 2018;142:89\u2013115.","journal-title":"Neuropharmacology"},{"key":"1328_CR60","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.neuropharm.2018.05.012","volume":"142","author":"MW Johnson","year":"2018","unstructured":"Johnson MW, Griffiths RR, Hendricks PS, Henningfield JE. The abuse potential of medical psilocybin according to the 8 factors of the controlled substances act. Neuropharmacology. 2018;142:143\u201366.","journal-title":"Neuropharmacology"},{"issue":"6","key":"1328_CR61","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1177\/0269881108093587","volume":"22","author":"M Johnson","year":"2008","unstructured":"Johnson M, Richards W, Griffiths R. Human hallucinogen research: guidelines for safety. J Psychopharmacol. 2008;22(6):603\u201320.","journal-title":"J Psychopharmacol"},{"issue":"6","key":"1328_CR62","doi-asserted-by":"publisher","first-page":"e13229","DOI":"10.1111\/adb.13229","volume":"27","author":"J Calleja-Conde","year":"2022","unstructured":"Calleja-Conde J, Morales-Garc\u00eda JA, Echeverry-Alzate V, B\u00fchler KM, Gin\u00e9 E, L\u00f3pez-Moreno JA. Classic psychedelics and alcohol use disorders: a systematic review of human and animal studies. Addict Biol. 2022;27(6):e13229.","journal-title":"Addict Biol"},{"issue":"6","key":"1328_CR63","doi-asserted-by":"publisher","first-page":"1767","DOI":"10.1007\/s00213-022-06063-2","volume":"239","author":"D Daldegan-Bueno","year":"2022","unstructured":"Daldegan-Bueno D, Maia LO, Massarentti CM, T\u00f3foli LF. Ayahuasca and tobacco smoking cessation: results from an online survey in Brazil. Psychopharmacology. 2022;239(6):1767\u201382.","journal-title":"Psychopharmacology"},{"issue":"1","key":"1328_CR64","first-page":"24","volume":"44","author":"TK Brown","year":"2018","unstructured":"Brown TK, Alper K. Treatment of opioid use disorder with ibogaine: Detoxification and drug use outcomes. AJDAA. 2018;44(1):24\u201336.","journal-title":"AJDAA"},{"issue":"11","key":"1328_CR65","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1177\/0269881114552713","volume":"28","author":"EE Schenberg","year":"2014","unstructured":"Schenberg EE, de Castro Comis MA, Chaves BR, da Silveira DX. Treating drug dependence with the aid of ibogaine: a retrospective study. J Psychopharmacol. 2014;28(11):993\u20131000.","journal-title":"J Psychopharmacol"},{"issue":"2","key":"1328_CR66","first-page":"401","volume":"42","author":"BJ Rodr\u00edguez-Cano","year":"2023","unstructured":"Rodr\u00edguez-Cano BJ, Kohek M, Ona G, Alc\u00e1zar-C\u00f3rcoles M\u00c1, dos Santos RG, Hallak JEC, et al. Underground ibogaine use for the treatment of substance use disorders: A qualitative analysis of subjective experiences. DAR. 2023;42(2):401\u201314.","journal-title":"DAR"},{"issue":"5","key":"1328_CR67","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1080\/02791072.2017.1361559","volume":"49","author":"A Lafrance","year":"2017","unstructured":"Lafrance A, Loizaga-Velder A, Fletcher J, Renelli M, Files N, Tupper KW. Nourishing the spirit: Exploratory research on ayahuasca experiences along the continuum of recovery from eating disorders. J Psychoactive Drugs. 2017;49(5):427\u201335.","journal-title":"J Psychoactive Drugs"},{"key":"1328_CR68","doi-asserted-by":"publisher","first-page":"2273","DOI":"10.3389\/fpsyg.2017.02273","volume":"8","author":"EC Gregertsen","year":"2017","unstructured":"Gregertsen EC, Mandy W, Serpell L. The egosyntonic nature of anorexia: an impediment to recovery in anorexia nervosa treatment. Front Psychol. 2017;8:2273.","journal-title":"Front Psychol"},{"issue":"2","key":"1328_CR69","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1007\/s40519-015-0235-7","volume":"21","author":"HM Espel","year":"2016","unstructured":"Espel HM, Goldstein SP, Manasse SM, Juarascio AS. Experiential acceptance, motivation for recovery, and treatment outcome in eating disorders. Eat Weight Disord. 2016;21(2):205\u201310.","journal-title":"Eat Weight Disord"},{"issue":"1","key":"1328_CR70","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1037\/a0029703","volume":"122","author":"KC Berg","year":"2013","unstructured":"Berg KC, Crosby RD, Cao L, Peterson CB, Engel SG, Mitchell JE, et al. Facets of negative affect prior to and following binge-only, purge-only, and binge\/purge events in women with bulimia nervosa. J Abnorm Psychol. 2013;122(1):111\u20138.","journal-title":"J Abnorm Psychol"},{"issue":"1","key":"1328_CR71","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/2050-2974-1-21","volume":"1","author":"ME Nowakowski","year":"2013","unstructured":"Nowakowski ME, McFarlane T, Cassin S. Alexithymia and eating disorders: a critical review of the literature. J Eat Disord. 2013;1(1):21.","journal-title":"J Eat Disord"},{"issue":"1","key":"1328_CR72","first-page":"21","volume":"1","author":"M Tantillo","year":"2013","unstructured":"Tantillo M, Sanftner J, Hauenstein E. Restoring connection in the face of disconnection: an integrative approach to understanding and treating anorexia nervosa. EDJTP. 2013;1(1):21\u201338.","journal-title":"EDJTP"},{"issue":"1","key":"1328_CR73","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/s40337-023-00736-9","volume":"11","author":"EB Barko","year":"2023","unstructured":"Barko EB, Moorman SM. Weighing in: qualitative explorations of weight restoration as recovery in anorexia nervosa. J Eat Disord. 2023;11(1):14.","journal-title":"J Eat Disord"},{"issue":"11","key":"1328_CR74","doi-asserted-by":"publisher","first-page":"e0313619","DOI":"10.1371\/journal.pone.0313619","volume":"19","author":"LG Brokj\u00f8b","year":"2024","unstructured":"Brokj\u00f8b LG, Cornelissen PL, Guman\u010d\u00edk J, McCarty K, Tov\u00e9e MJ, Cornelissen KK. Evidence for a specific distortion in perceptual body image in eating disorders: a replication and extension. PLoS ONE. 2024;19(11):e0313619.","journal-title":"PLoS ONE"},{"issue":"5","key":"1328_CR75","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1007\/s40519-020-00977-6","volume":"26","author":"B Demartini","year":"2021","unstructured":"Demartini B, Nistic\u00f2 V, Tedesco R, Marzorati A, Ferrucci R, Priori A, et al. Visual perception and dissociation during mirror gazing test in patients with anorexia nervosa: a preliminary study. Eat Weight Disord. 2021;26(5):1541\u201351.","journal-title":"Eat Weight Disord"},{"issue":"1","key":"1328_CR76","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1007\/s40519-021-01122-7","volume":"27","author":"T Fuchs","year":"2022","unstructured":"Fuchs T. The disappearing body: anorexia as a conflict of embodiment. Eat Weight Disord. 2022;27(1):109\u201317.","journal-title":"Eat Weight Disord"},{"issue":"1\u20132","key":"1328_CR77","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1080\/00223980.2011.606435","volume":"146","author":"MP Levine","year":"2012","unstructured":"Levine MP. Loneliness and eating disorders. J Psychol. 2012;146(1\u20132):243\u201357.","journal-title":"J Psychol"},{"issue":"2","key":"1328_CR78","doi-asserted-by":"publisher","first-page":"142","DOI":"10.3390\/psychiatryint3020012","volume":"3","author":"E Makri","year":"2022","unstructured":"Makri E, Michopoulos I, Gonidakis F. Investigation of loneliness and social support in patients with eating disorders: a case-control study. Psychiatry Int. 2022;3(2):142\u201357.","journal-title":"Psychiatry Int"},{"issue":"12","key":"1328_CR79","doi-asserted-by":"publisher","first-page":"1678","DOI":"10.1002\/eat.23793","volume":"55","author":"L Cort\u00e9s-Garc\u00eda","year":"2022","unstructured":"Cort\u00e9s-Garc\u00eda L, Rodr\u00edguez-Cano R, von Soest T. Prospective associations between loneliness and disordered eating from early adolescence to adulthood. Int J Eat Disord. 2022;55(12):1678\u201389.","journal-title":"Int J Eat Disord"},{"issue":"2","key":"1328_CR80","first-page":"96","volume":"20","author":"G Budd","year":"2007","unstructured":"Budd G. Disordered eating: young women\u2019s search for control and connection. JCAPN. 2007;20(2):96\u2013106.","journal-title":"JCAPN"},{"issue":"7","key":"1328_CR81","doi-asserted-by":"publisher","first-page":"1603","DOI":"10.3390\/nu15071603","volume":"15","author":"A Pelc","year":"2023","unstructured":"Pelc A, Winiarska M, Polak-Szczyby\u0142o E, Godula J, St\u0119pie\u0144 AE. Low self-esteem and life satisfaction as a significant risk factor for eating disorders among adolescents. Nutrients. 2023;15(7):1603.","journal-title":"Nutrients"},{"issue":"1","key":"1328_CR82","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1002\/eat.20009","volume":"36","author":"J Castro","year":"2004","unstructured":"Castro J, Gila A, Puig J, Rodriguez S, Toro J. Predictors of rehospitalization after total weight recovery in adolescents with anorexia nervosa. Int J Eat Disord. 2004;36(1):22\u201330.","journal-title":"Int J Eat Disord"},{"issue":"8","key":"1328_CR83","doi-asserted-by":"publisher","first-page":"2513","DOI":"10.1007\/s40519-021-01118-3","volume":"26","author":"E Rossi","year":"2021","unstructured":"Rossi E, Castellini G, Cassioli E, Sensi C, Mancini M, Stanghellini G, et al. The role of embodiment in the treatment of patients with anorexia and bulimia nervosa: A 2-year follow-up study proposing an integration between enhanced cognitive behavioural therapy and a phenomenological model of eating disorders. Eat Weight Disord. 2021;26(8):2513\u201322.","journal-title":"Eat Weight Disord"},{"key":"1328_CR84","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.brat.2014.02.006","volume":"56","author":"EC Accurso","year":"2014","unstructured":"Accurso EC, Ciao AC, Fitzsimmons-Craft EE, Lock JD, Le Grange D. Is weight gain really a catalyst for broader recovery?: The impact of weight gain on psychological symptoms in the treatment of adolescent anorexia nervosa. Behav Res Ther. 2014;56:1\u20136.","journal-title":"Behav Res Ther"},{"issue":"2","key":"1328_CR85","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1023\/B:CSOW.0000024327.55424.a9","volume":"32","author":"W Stewart","year":"2004","unstructured":"Stewart W. The role of perceived loneliness and isolation in the relapse from recovery in patients with anorexia and bulimia nervosa. Clin Soc Work J. 2004;32(2):185\u201396.","journal-title":"Clin Soc Work J"},{"issue":"4","key":"1328_CR86","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1037\/0022-006X.61.4.696","volume":"61","author":"CG Fairburn","year":"1993","unstructured":"Fairburn CG, Peveler RC, Jones R, Hope RA, Doll HA. Predictors of 12-month outcome in bulimia nervosa and the influence of attitudes to shape and weight. J Consult Clin Psychol. 1993;61(4):696\u20138.","journal-title":"J Consult Clin Psychol"},{"issue":"1","key":"1328_CR87","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s13030-018-0134-z","volume":"12","author":"N Kodama","year":"2018","unstructured":"Kodama N, Moriguchi Y, Takeda A, Maeda M, Ando T, Kikuchi H, et al. Neural correlates of body comparison and weight estimation in weight-recovered anorexia nervosa: a functional magnetic resonance imaging study. Biopsychosoc Med. 2018;12(1):15.","journal-title":"Biopsychosoc Med"},{"issue":"3","key":"1328_CR88","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1080\/10640266.2012.668480","volume":"20","author":"D Linville","year":"2012","unstructured":"Linville D, Brown T, Sturm K, McDougal T. Eating disorders and social support: perspectives of recovered individuals. Eat Disord. 2012;20(3):216\u201331.","journal-title":"Eat Disord"},{"issue":"1","key":"1328_CR89","doi-asserted-by":"publisher","first-page":"22479","DOI":"10.1038\/s41598-021-01811-4","volume":"11","author":"JM Rootman","year":"2021","unstructured":"Rootman JM, Kryskow P, Harvey K, Stamets P, Santos-Brault E, Kuypers KPC, et al. Adults who microdose psychedelics report health related motivations and lower levels of anxiety and depression compared to non-microdosers. Sci Rep. 2021;11(1):22479.","journal-title":"Sci Rep"},{"issue":"1","key":"1328_CR90","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1038\/s41398-022-02039-0","volume":"12","author":"F Cavanna","year":"2022","unstructured":"Cavanna F, Muller S, de la Fuente LA, Zamberlan F, Palmucci M, Janeckova L, et al. Microdosing with psilocybin mushrooms: a double-blind placebo-controlled study. Transl Psychiatry. 2022;12(1):307.","journal-title":"Transl Psychiatry"},{"issue":"6","key":"1328_CR91","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1016\/j.biopsych.2023.03.013","volume":"94","author":"RJ Murphy","year":"2023","unstructured":"Murphy RJ, Sumner R, Evans W, Ponton R, Ram S, Godfrey K, et al. Acute mood-elevating properties of microdosed lysergic acid diethylamide in healthy volunteers: a home-administered randomized controlled trial. Biol Psychiatry. 2023;94(6):511\u201321.","journal-title":"Biol Psychiatry"},{"issue":"16","key":"1328_CR92","doi-asserted-by":"publisher","first-page":"7619","DOI":"10.1017\/S0033291723001411","volume":"53","author":"P McCrone","year":"2023","unstructured":"McCrone P, Fisher H, Knight C, Harding R, Schlag AK, Nutt DJ, et al. Cost-effectiveness of psilocybin-assisted therapy for severe depression: exploratory findings from a decision analytic model. Psychol Med. 2023;53(16):7619\u201326.","journal-title":"Psychol Med"},{"issue":"9","key":"1328_CR93","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1177\/02698811231190865","volume":"37","author":"M Tagen","year":"2023","unstructured":"Tagen M, Mantuani D, van Heerden L, Holstein A, Klumpers LE, Knowles R. The risk of chronic psychedelic and MDMA microdosing for valvular heart disease. J Psychopharmacol. 2023;37(9):876\u201390.","journal-title":"J Psychopharmacol"},{"issue":"3","key":"1328_CR94","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1177\/02698811231225609","volume":"38","author":"A Rouaud","year":"2024","unstructured":"Rouaud A, Calder AE, Hasler G. Microdosing psychedelics and the risk of cardiac fibrosis and valvulopathy: comparison to known cardiotoxins. J Psychopharmacol. 2024;38(3):217\u201324.","journal-title":"J Psychopharmacol"},{"issue":"12","key":"1328_CR95","doi-asserted-by":"publisher","first-page":"e2451094","DOI":"10.1001\/jamanetworkopen.2024.51094","volume":"7","author":"MCM Tseng","year":"2024","unstructured":"Tseng MCM, Chiou KR, Shao JYH, Liu HY. Incidence and risk of cardiovascular outcomes in patients with anorexia nervosa. JAMA Netw Open. 2024;7(12):e2451094\u2013e2451094.","journal-title":"JAMA Netw Open"},{"issue":"3","key":"1328_CR96","doi-asserted-by":"publisher","first-page":"88","DOI":"10.4103\/1995-705X.164463","volume":"16","author":"MR Sardar","year":"2015","unstructured":"Sardar MR, Greway A, DeAngelis M, Tysko EO, Lehmann S, Wohlstetter M, et al. Cardiovascular impact of eating disorders in adults: a single center experience and literature review. Heart Views. 2015;16(3):88\u201392.","journal-title":"Heart Views"},{"key":"1328_CR97","doi-asserted-by":"publisher","first-page":"782","DOI":"10.3389\/fpsyt.2020.00782","volume":"11","author":"RJ Zeifman","year":"2020","unstructured":"Zeifman RJ, Wagner AC, Watts R, Kettner H, Mertens LJ, Carhart-Harris RL. Post-psychedelic reductions in experiential avoidance are associated with decreases in depression severity and suicidal ideation. Front Psychiatry. 2020;11:782.","journal-title":"Front Psychiatry"},{"issue":"12","key":"1328_CR98","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1177\/0269881116662634","volume":"30","author":"TM Carbonaro","year":"2016","unstructured":"Carbonaro TM, Bradstreet MP, Barrett FS, MacLean KA, Jesse R, Johnson MW, et al. Survey study of challenging experiences after ingesting psilocybin mushrooms: acute and enduring positive and negative consequences. J Psychopharmacol. 2016;30(12):1268\u201378.","journal-title":"J Psychopharmacol"},{"key":"1328_CR99","doi-asserted-by":"publisher","first-page":"116381","DOI":"10.1016\/j.psychres.2025.116381","volume":"345","author":"F M\u00fcller","year":"2025","unstructured":"M\u00fcller F, Sauer T, H\u00e4nny C, M\u00fchlhauser M, Lang UE. Suicide of a patient shortly after psilocybin-assisted psychedelic therapy: a case report. Psychiatry Res. 2025;345:116381.","journal-title":"Psychiatry Res"},{"issue":"6","key":"1328_CR100","doi-asserted-by":"publisher","first-page":"e229","DOI":"10.1192\/bjo.2024.768","volume":"10","author":"M Wahba","year":"2024","unstructured":"Wahba M, Hayes C, Kletter M, McAllister-Williams RH. Worsening suicidal ideation and prolonged adverse event following psilocybin administration in a clinical setting: Case report and thematic analysis of one participant\u2019s experience. BJPsych Open. 2024;10(6):e229.","journal-title":"BJPsych Open"},{"issue":"9","key":"1328_CR101","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1001\/jama.2023.14530","volume":"330","author":"CL Raison","year":"2023","unstructured":"Raison CL, Sanacora G, Woolley J, Heinzerling K, Dunlop BW, Brown RT, et al. Single-dose psilocybin treatment for major depressive disorder: a randomized clinical trial. JAMA. 2023;330(9):843\u201353.","journal-title":"JAMA"},{"issue":"4","key":"1328_CR102","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1017\/S0033291718001356","volume":"49","author":"F Palhano-Fontes","year":"2019","unstructured":"Palhano-Fontes F, Barreto D, Onias H, Andrade KC, Novaes MM, Pessoa JA, et al. Rapid antidepressant effects of the psychedelic ayahuasca in treatment-resistant depression: a randomized placebo-controlled trial. Psychol Med. 2019;49(4):655\u201363.","journal-title":"Psychol Med"},{"issue":"3","key":"1328_CR103","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/j.biopsych.2022.08.025","volume":"93","author":"F Holze","year":"2023","unstructured":"Holze F, Gasser P, M\u00fcller F, Dolder PC, Liechti ME. Lysergic acid diethylamide\u2013assisted therapy in patients with anxiety With and without a life-threatening Illness: a randomized, double-blind, placebo-controlled phase II study. Biol Psychiatry. 2023;93(3):215\u201323.","journal-title":"Biol Psychiatry"},{"issue":"8","key":"1328_CR104","doi-asserted-by":"publisher","first-page":"1717","DOI":"10.1017\/S0033291723003653","volume":"54","author":"B Szigeti","year":"2024","unstructured":"Szigeti B, Weiss B, Rosas FE, Erritzoe D, Nutt D, Carhart-Harris R. Assessing expectancy and suggestibility in a trial of escitalopram v. psilocybin for depression. Psychol Med. 2024;54(8):1717\u201324.","journal-title":"Psychol Med"},{"issue":"5","key":"1328_CR105","first-page":"512","volume":"9","author":"B Szigeti","year":"2024","unstructured":"Szigeti B, Heifets BD. Expectancy effects in psychedelic trials. Biol Psychiatry Cogn Neurosci Neuroimaging. 2024;9(5):512\u201321.","journal-title":"Biol Psychiatry Cogn Neurosci Neuroimaging"},{"key":"1328_CR106","doi-asserted-by":"publisher","first-page":"204512532311984","DOI":"10.1177\/20451253231198466","volume":"13","author":"M van Elk","year":"2023","unstructured":"van Elk M, Fried EI. History repeating: guidelines to address common problems in psychedelic science. Ther Adv Psychopharmacol. 2023;13:20451253231198464.","journal-title":"Ther Adv Psychopharmacol"}],"container-title":["Journal of Eating Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40337-025-01328-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40337-025-01328-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40337-025-01328-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,7]],"date-time":"2025-09-07T23:12:52Z","timestamp":1757286772000},"score":1,"resource":{"primary":{"URL":"https:\/\/jeatdisord.biomedcentral.com\/articles\/10.1186\/s40337-025-01328-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,24]]},"references-count":106,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1328"],"URL":"https:\/\/doi.org\/10.1186\/s40337-025-01328-5","relation":{},"ISSN":["2050-2974"],"issn-type":[{"value":"2050-2974","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,24]]},"assertion":[{"value":"12 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The survey was approved by the Human ethics review board of the University of Sydney (2022\/526) and all participants consented to participate.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}},{"value":"Participants provided consent for the use of their data in publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"AS has received consulting fees from the Medical Cannabis Industry Australia (MCIA) and Haleon (consumer healthcare subsidiary of Glaxo Smith-Kline). SM and SR has salary support from NHMRC. ISM is the Academic Director of the Lambert Initiative for Cannabinoid Therapeutics. He has served as an expert witness in various medicolegal cases involving cannabis and has received consulting fees from Medical Cannabis Industry Australia (MCIA), Althea, and Janssen. He has acted as an advisor\/consultant to Kinoxis Therapeutics, Psylo, and Emyria and has had salary support from the NHMRC and from Lambert Initiative for Cannabinoid Therapeutics. He is an inventor on patents WO2017004674, WO2018107216, WO2020102857 and AU2022240104 licensed to Kinoxis Therapeutics, involving the use of novel small molecules to treat addictions, social deficits, opioid withdrawal and aggression. He is an inventor on issued patents WO2019227167 and WO2019071302 which relate to cannabinoid therapeutics. MBP, KG, NM, NS have no conflicts to declare.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"152"}}